STOCK TITAN

Curevac B.V. - CVAC STOCK NEWS

Welcome to our dedicated page for Curevac B.V. news (Ticker: CVAC), a resource for investors and traders seeking the latest updates and insights on Curevac B.V. stock.

CureVac B.V. (CVAC) is a clinical-stage biopharmaceutical leader pioneering mRNA technology for vaccines and cancer therapies. This page provides investors and industry professionals with timely updates on corporate developments, regulatory milestones, and scientific advancements.

Access verified press releases, earnings reports, and partnership announcements in one centralized location. Track progress across CureVac's clinical pipeline, including prophylactic vaccines, oncology treatments, and molecular therapies leveraging their proprietary mRNA platform.

Key updates cover:

• Clinical trial results
• Strategic collaborations with global partners
• Regulatory filings and manufacturing developments
• Financial performance and corporate communications

Bookmark this page for direct access to CureVac's official announcements, ensuring you stay informed about innovations in mRNA-based medicine and their market implications.

Rhea-AI Summary

CureVac and GSK have initiated a Phase 1 dose-escalation study for their second-generation COVID-19 vaccine candidate CV2CoV in the U.S., with the first participant dosed. This trial is crucial to evaluate the candidate's safety and immune response, building on promising preclinical data that suggests better efficacy compared to the first-generation vaccine. The study aims to enroll 210 healthy adults, with results anticipated in the second half of 2022, marking a significant step in advancing mRNA vaccine technology.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.52%
Tags
clinical trial covid-19
-
Rhea-AI Summary

CureVac N.V. (NASDAQ:CVAC) has launched CureVac RNA Printer GmbH, a wholly-owned subsidiary designed to enhance the development and operational capacity of The RNA Printer(R), an automated RNA vaccine and therapeutic manufacturing solution. This initiative aims to facilitate rapid access to mRNA technology, particularly in pandemic situations and personalized therapies. Dr. Markus Bergmann has been appointed General Manager, bringing extensive expertise in business development and a medical background. The announcement highlights CureVac's commitment to expanding its footprint in the mRNA market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.43%
Tags
none
-
Rhea-AI Summary

CureVac (NASDAQ: CVAC) has initiated a Phase 1 study for its seasonal influenza mRNA vaccine candidate CVSQIV, dosing the first participant in Panama. This vaccine, developed in partnership with GSK, employs a multivalent approach to target four different influenza strains using non-chemically modified mRNA. The study aims to enroll up to 240 healthy adults to assess the safety and immune response. The collaboration focuses on enhancing mRNA vaccine technologies for infectious diseases, building on the successful application during the COVID-19 pandemic.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.18%
Tags
Rhea-AI Summary

CureVac N.V. (NASDAQ:CVAC) announced the resignation of Chief Technology Officer Dr. Mariola Fotin-Mleczek, effective January 31, 2022, after nearly 16 years with the company. She is transitioning to a family business in Poland. Dr. Igor Splawski, Chief Scientific Officer, will lead the continued development of CureVac's mRNA technology. The company's innovative mRNA platform has contributed significantly to medical advancements, including vaccines and therapies across various therapeutic areas. CureVac has a strong pipeline and is focused on leveraging its mRNA technology for future growth.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

BERLIN, GERMANY / ACCESSWIRE / January 13, 2022 / dievini and the Federal Republic of Germany have amended their shareholders' agreement regarding CureVac N.V. (NASDAQ:CVAC). This update follows the succession planning for Dietmar Hopp's estate, resulting in dievini's ownership being transferred to the Hopp family. The agreement details shareholder voting behavior and board appointments. dievini plans to sell CureVac shares to finance restructuring, although no current sales to third parties are expected. dievini holds about 42% of CureVac's common shares.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.43%
Tags
none
-
Rhea-AI Summary

CureVac N.V. (NASDAQ: CVAC) announced its strategic shift towards developing a second-generation mRNA COVID-19 vaccine, CV2CoV, in collaboration with GSK, following the withdrawal of its first-generation candidate, CVnCoV, from regulatory review. The company reported a cash position of €1.06 billion as of September 30, 2021, despite a substantial increase in operating losses, which reached €143.1 million for Q3 2021. Promising preclinical results published in Nature show CV2CoV's immune response is comparable to an approved mRNA vaccine, enhancing CureVac's position in the mRNA vaccine space.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.05%
Tags
Rhea-AI Summary

CureVac (NASDAQ:CVAC) has published new preclinical data for its second-generation COVID-19 vaccine candidate, CV2CoV, developed with GSK, in Nature. The study shows antibody levels after vaccination with 12μg of CV2CoV are comparable to those following a 30μg dose of Comirnaty® (Pfizer/BioNTech). CV2CoV demonstrated enhanced immune responses, with better neutralizing capacity against variants like Delta. This research underscores the potential of non-chemically modified mRNA technology in vaccine development.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.9%
Tags
clinical trial covid-19
-
Rhea-AI Summary

CureVac recently reported promising outcomes from the Phase 1 clinical trial of its oncology candidate CV8102, indicating a systemic immune response in both injected and non-injected tumors. The completed dose-escalation study demonstrated significant stimulation of the immune system, with increased T cell infiltration observed in biopsy samples. The expansion phase, fully recruited by October 2021, includes 40 patients and aims to confirm CV8102's safety and efficacy. Results from this study are anticipated in the second half of 2022.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.51%
Tags
-
Rhea-AI Summary

CureVac N.V. (CVAC) has announced a strategic pivot in its COVID-19 vaccine efforts, prioritizing the development of second-generation mRNA vaccine candidates in partnership with GSK. The company will withdraw its first-generation vaccine candidate, CVnCoV, from regulatory review due to potential overlaps with approval timelines for newer candidates. CureVac expects the second-generation program to enter clinical development soon and aims for market readiness in 2022, with reported pre-clinical data indicating up to 10x higher immunogenicity than CVnCoV.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.61%
Tags
covid-19
Rhea-AI Summary

CureVac has announced a strategic adjustment to its European manufacturing network in response to decreased demand for its COVID-19 vaccine candidate, CVnCoV, currently under review by the EMA. The company is terminating contracts with WACKER and Celonic while maintaining agreements with Rentschler Biopharma and Novartis. This move aims to align manufacturing capacity with actual demand. Vaccine production for the second-generation COVID-19 candidate, CV2CoV, developed with GSK, remains unaffected and is expected to enter clinical trials in Q4 2021.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.02%
Tags
none
Curevac B.V.

Nasdaq:CVAC

CVAC Rankings

CVAC Stock Data

702.49M
123.61M
45.26%
18.01%
1.74%
Biotechnology
Healthcare
Link
Germany
Tübingen